Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Absorica Generic

<< Previous

Bullboard Posts

Next >>

Post by pabalooon Dec 31, 2020 12:20pm

204 Views

Post# 32203878

Absorica Generic

So Activis/Teva have not submitted to launch a generic of Absorica as of yet? They could be selling as of December 27 but have not even looked for FDA approval as far as I can see. This leaves 9 more months of sales to Sun and Cipher. It will hopefully rule out other pharmas from entering this space as it may be too small a margin to profit trying to compete if Sun reduced prices.
looks like another few quarters of 4 million in revenue and .10 in profit.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant